APA aipamena

Guo, R., Berry, L. D., Aisner, D. L., Sheren, J., Boyle, T., Bunn, P. A., . . . Kris, M. G. (2019). MET IHC is a Poor Screen for MET Amplification or MET exon 14 mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium. J Thorac Oncol.

Chicago Style aipamena

Guo, Robin, et al. "MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data From a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium." J Thorac Oncol 2019.

MLA aipamena

Guo, Robin, et al. "MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data From a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium." J Thorac Oncol 2019.